Cytek Biosciences, Inc.
CTKB Healthcare Medical Devices
Cytek Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $201.5 million, up 0.52% from fiscal 2024. In the quarter to June 2026, revenue grew 5.57%, EPS fell 125.0%, free cash flow grew 42.5% and total debt fell 68.9%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow CTKB
Cytek Biosciences, Inc. (CTKB) Piotroski F-score
Cytek Biosciences, Inc.'s Piotroski F-score for fiscal 2025 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, down from 6 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 4 | (2.00) |
| FY2024 | 6 | 2.00 |
| FY2023 | 4 | 2.00 |
| FY2022 | 2 | (3.00) |
| FY2021 | 5 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (13.85%) | (1.21%) | Fail | 0 |
| Positive operating cash flow | (4.69m) | 25.38m | Fail | 0 |
| Rising return on assets | (13.85%) | (1.21%) | Fail | 0 |
| Cash flow above net income | 61.85m | 31.40m | Pass | 1 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 5.04 | 5.86 | Fail | 0 |
| No new shares issued | 127,746,000 | 130,611,000 | Pass | 1 |
| Rising gross margin | 51.84% | 55.43% | Fail | 0 |
| Rising asset turnover | 0.42 | 0.40 | Pass | 1 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| TCMD Tactile Systems Technology, Inc. compare | 8 |
| SIBN SiBone compare | 6 |
| VREX VAREX IMAGING compare | 6 |
| BBNX Beta Bionics, Inc. compare | 5 |
| KIDS OrthoPediatrics Corp. compare | 4 |
| CTKB Cytek Biosciences, Inc. | 4 |
| INMD InMode Ltd. compare | 4 |
| AHCO AdaptHealth Corp. compare | 4 |
| PACB Pacific Biosciences of California, Inc. compare | 3 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover